Quote this publication Share Print

AFINITOR

-
Opinions on drugs - Posted on Dec 22 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use.

-


Clinical Benefit

Substantial

The actual benefit is substantial.


Clinical Added Value

minor

AFINITOR offers a minor IAB (grade IV) in treatment strategy in the treatment of advanced renal cancer following failure of VEGF-targeted therapy.


Contact Us

Évaluation des médicaments

See also